Treatment of Inflammatory Bowel Disease with Biologics
277 clinical use [ 66 ]. Because of the greater costs and time for research and develop- ment for a given biosimilar, the most i ...
278 RA and psoriasis for ABP 501, without any primary RCT data existing in IBD, though these trials are now underway. Health Can ...
279 guidancecomplianceregulatoryinformation/guidances/ucm397017.pdf.Last Updated May 2014. Food & Drug Administration. Guid ...
280 St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrex- ate therapy for early rheumatoid ...
281 Food & Drug Administration. Biosimilars: additional questions and answers regarding imple- mentation of the biologics p ...
282 VanArnumP. Biosimilars: market weaknesses and strengths. http://www.pharmtech.com/ biosimilars- market-weaknesses-and-stre ...
© Springer International Publishing AG 2018 283 A.S. Cheifetz, J.D. Feuerstein (eds.), Treatment of Inflammatory Bowel Disease w ...
284 Tissue injury in Crohn’s disease (CD) and ulcerative colitis (UC) occurs in areas heavily infiltrated with subsets of activa ...
285 Integrins involved in T-cell migration are leucocyte function-associated antigen 1 (LFA-1 or α 2 β2) and the two α4 integrin ...
286 Natalizumab Natalizumab is a recombinant humanised monoclonal IgG4 antibody against the integrin subunit α4 that blocks both ...
287 efficacious for anti-TNF-naive (RR, 0.87; 95% CI, 0.75–1.00) and anti-TNF- exposed (RR, 0.86; 95% CI, 0.76–0.99) patients. A ...
288 estimated at 50% by 30 years and 68% by 70 years [ 30 ]. The main risk factors for PML in natalizumab-treated patients in ad ...
289 In the CD study in 185 patients, the primary efficacy endpoint of clinical response (>70-point decrement in the CDAI scor ...
290 The GEMINI III trial enrolled patients with moderately to severely active CD, the majority of who (76%) had failed anti-TNF ...
291 trial showing reduced seroconversion following oral cholera vaccination against cholera toxin but no attenuation of serologi ...
292 patients in whom the concomitant use of bridging strategies (such as co-induction with steroids) is possible and where surge ...
293 consequences of which are presently unknown. This could have implications on vaccination against enteric infections such as ...
294 PF-00547659 (Anti-MAdCAM-1) PF-00547659 is a monoclonal IgG2 antibody directed against MAdCAM-1. MAdCAM-1 is expressed on va ...
295 endpoint of clinical remission at either treatment dose in comparison to placebo (4.3% in the pooled etrolizumab treatment g ...
296 The first evaluation of alicaforsen in UC, a randomised double-blind placebo- controlled escalating dose trial of 40 patient ...
«
8
9
10
11
12
13
14
15
16
17
»
Free download pdf